Literature DB >> 7984150

An extracellular congenital nephrogenic diabetes insipidus mutation of the vasopressin receptor reduces cell surface expression, affinity for ligand, and coupling to the Gs/adenylyl cyclase system.

M Birnbaumer1, S Gilbert, W Rosenthal.   

Abstract

The mutation of the type-2 vasopressin receptor (V2R) apparently responsible for X-linked congenital nephrogenic diabetes insipidus (CNDI) in the Q3 family consists of a T to C transition in codon 113, causing the change of Arg-113 to Trp. Arg-113 is located in the putative first extracellular loop of the V2R next to a frequently conserved Cys thought to interact via a disulfide bridge with a Cys of the second extracellular loop. The present study explored whether this mutation may account for the CNDI phenotype. The mutation was excised from the genomic DNA of a Q3 patient and introduced into the V2R cDNA, which was then placed into an expression plasmid and transfected into COS cells for transient expression and murine L cells for stable expression. Studies with L cells expressing similar levels of wild type and Q3 receptors showed that the mutant receptor has a 20-fold reduced affinity for arginine vasopressin (AVP) and stimulates adenylyl cyclase with an EC50 that is increased by a factor of about 60-fold. The same shift in the EC50 for adenylyl cyclase stimulation was obtained when deamino[8-D-Arg]vasopressin was substituted for AVP. Studies with COS cells revealed that at equal levels of transfected DNA, the mutant receptor is expressed at lower levels (about 20%) than the wild type receptor, indicating that the mutation hinders the transport of the receptor to the cell membrane.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7984150     DOI: 10.1210/mend.8.7.7984150

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  17 in total

Review 1.  Genetic variations in human G protein-coupled receptors: implications for drug therapy.

Authors:  W Sadee; E Hoeg; J Lucas; D Wang
Journal:  AAPS PharmSci       Date:  2001

2.  Molecular Architecture of G Protein-Coupled Receptors.

Authors:  A Michiel van Rhee; Kenneth A Jacobson
Journal:  Drug Dev Res       Date:  1996-01-01       Impact factor: 4.360

3.  Molecular recognition of peptide and non-peptide ligands by the extracellular domains of neurohypophysial hormone receptors.

Authors:  J Howl; M Wheatley
Journal:  Biochem J       Date:  1996-07-15       Impact factor: 3.857

4.  Nephrogenic syndrome of inappropriate antidiuresis.

Authors:  Brian J Feldman; Stephen M Rosenthal; Gabriel A Vargas; Raymond G Fenwick; Eric A Huang; Mina Matsuda-Abedini; Robert H Lustig; Robert S Mathias; Anthony A Portale; Walter L Miller; Stephen E Gitelman
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

5.  Phosphorylation analysis of G protein-coupled receptor by mass spectrometry: identification of a phosphorylation site in V2 vasopressin receptor.

Authors:  Shilan Wu; Mariel Birnbaumer; Ziqiang Guan
Journal:  Anal Chem       Date:  2008-06-26       Impact factor: 6.986

6.  Pharmacological analysis of human D1 AND D2 dopamine receptor missense variants.

Authors:  Munya A Al-Fulaij; Yong Ren; Martin Beinborn; Alan S Kopin
Journal:  J Mol Neurosci       Date:  2008-01-18       Impact factor: 3.444

7.  Properties of the human arginine vasopressin V2 receptor after site-directed mutagenesis of its putative palmitoylation site.

Authors:  R Schülein; U Liebenhoff; H Müller; M Birnbaumer; W Rosenthal
Journal:  Biochem J       Date:  1996-01-15       Impact factor: 3.857

8.  Binding-, intracellular transport-, and biosynthesis-defective mutants of vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes insipidus.

Authors:  H Tsukaguchi; H Matsubara; S Taketani; Y Mori; T Seido; M Inada
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

9.  Common α2A and α2C adrenergic receptor polymorphisms do not affect plasma membrane trafficking.

Authors:  Carl M Hurt; Matt W Sorensen; Timothy Angelotti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-03-19       Impact factor: 3.000

Review 10.  Elucidating Solution Structures of Cyclic Peptides Using Molecular Dynamics Simulations.

Authors:  Jovan Damjanovic; Jiayuan Miao; He Huang; Yu-Shan Lin
Journal:  Chem Rev       Date:  2021-01-11       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.